ADLARITY^® is applied
once per week¹

INITIATING PATIENTS ON ADLARITY APPLICATION SITE FLEXIBILITY

5-mg and 10-mg once-weekly ADLARITY® transdermal system.

Not actual size.

Available in 5-mg and 10-mg strengths.

One once-weekly ADLARITY transdermal system replaces 7 days of oral donepezil 5 mg/d or 10 mg/d tablets.

Starting ADLARITY

The recommended starting dose of ADLARITY is 5 mg/d
After 4 to 6 weeks, the dose may be increased to the maximum dose of 10 mg/d

Switching to ADLARITY from oral donepezil

Patients treated with oral donepezil 5 mg/d can be switched to ADLARITY 5 mg/d once weekly
If the patient has been on oral donepezil 5 mg/d for at least 4 to 6 weeks or on oral donepezil 10
mg/d, the patient may be switched immediately to ADLARITY 10 mg/d once weekly

ADLARITY is conveniently administered without regard to food intake

ADLARITY offers patients and caregivers application site flexibility¹

Recommended application site

ADLARITY® may be applied to the back and upper buttocks.

Back and
upper buttocks

ADLARITY may be applied to the upper back below the shoulder blades (avoiding the spine), where it may be less likely to be removed by the patient.²

For patients who are able to self-apply or if
ADLARITY is not expected to be removed by
the patient before the full 7 days

ADLARITY® may be self-applied on the upper buttocks or the upper outer thigh.

Upper buttocks or the
upper outer thigh

ADLARITY may be
easily self-applied on
the upper buttocks or
the upper outer thigh.²

ADLARITY should be replaced every 7 days. Only 1 transdermal system should be worn at a time.¹

An application site should be chosen that has not been used in the past 14 days

See the Instructions for Use for step-by-step instructions.

ADLARITY use does not need to be interrupted due to bathing or hot weather. Avoid long exposure to external heat sources¹
Store ADLARITY in the refrigerator. Allow the pouch to reach room temperature before opening¹

Learn about the innovative
Corplex technology in
ADLARITY

Sign up for the latest
information about
ADLARITY

References: 1. ADLARITY. Prescribing information. Corium, Inc; 2022. 2. ADLARITY. Instructions for use. Corium, Inc; 2022.

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

IMPORTANT SAFETY INFORMATION

Contraindications

ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.

Warnings and Precautions

Application site skin reactions: ADLARITY may cause skin application-site reactions. These reactions are not necessarily indicative of sensitization; however, allergic contact dermatitis may occur and should be suspected if application-site reactions spread beyond the size of the transdermal system, there is evidence of a more intense local reaction, and symptoms do not significantly improve within 48 hours of transdermal system removal.
Anesthesia: ADLARITY, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.
Cardiovascular conditions: Cholinesterase inhibitors, including ADLARITY, may have vagotonic effects on the sinoatrial and atrioventricular nodes. These effects may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil.
Nausea and vomiting: Donepezil, the active ingredient in ADLARITY, may cause diarrhea, nausea, and vomiting. In most cases these effects have been transient, although some cases lasted 1 to 3 weeks. Patients should be monitored closely during initiation of treatment and after dose increases.
Peptic ulcer disease and gastrointestinal bleeding: Cholinesterase inhibitors, including ADLARITY, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
Genitourinary conditions: Although not observed in clinical trials of ADLARITY, bladder outflow obstruction may occur.
Seizures: Cholinomimetics, including ADLARITY, are believed to have some potential to cause generalized convulsions; however, seizure activity may also be a manifestation of Alzheimer's disease.
Pulmonary conditions: Cholinesterase inhibitors, including ADLARITY, should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

Adverse Reactions

The most common adverse reactions (greater than 5% with donepezil tablets and twice the placebo rate) are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.

Drug Interactions

Cholinesterase inhibitors, including donepezil, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088.

Please click here for Full Prescribing Information.

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

IMPORTANT SAFETY INFORMATION

Contraindications

ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.

Warnings and Precautions

Application site skin reactions: ADLARITY may cause skin application-site reactions. These reactions are not necessarily indicative of sensitization; however, allergic contact dermatitis may occur and should be suspected if application-site reactions spread beyond the size of the transdermal system, there is evidence of a more intense local reaction, and symptoms do not significantly improve within 48 hours of transdermal system removal.
Anesthesia: ADLARITY, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.
Cardiovascular conditions: Cholinesterase inhibitors, including ADLARITY, may have vagotonic effects on the sinoatrial and atrioventricular nodes. These effects may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil.
Nausea and vomiting: Donepezil, the active ingredient in ADLARITY, may cause diarrhea, nausea, and vomiting. In most cases these effects have been transient, although some cases lasted 1 to 3 weeks. Patients should be monitored closely during initiation of treatment and after dose increases.
Peptic ulcer disease and gastrointestinal bleeding: Cholinesterase inhibitors, including ADLARITY, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
Genitourinary conditions: Although not observed in clinical trials of ADLARITY, bladder outflow obstruction may occur.
Seizures: Cholinomimetics, including ADLARITY, are believed to have some potential to cause generalized convulsions; however, seizure activity may also be a manifestation of Alzheimer's disease.
Pulmonary conditions: Cholinesterase inhibitors, including ADLARITY, should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.

Adverse Reactions

The most common adverse reactions (greater than 5% with donepezil tablets and twice the placebo rate) are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.

Drug Interactions

Cholinesterase inhibitors, including donepezil, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088.

Please click here for Full Prescribing Information.